Abstract
Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) immune checkpoint pathway prevent T-cell downregulation and promote immune responses against cancer. Several PD-1 pathway inhibitors have shown robust activity in initial trials. This article reviews the preclinical evidence, rationale, and clinical pharmacology of blockade of PD-1 or its ligands as therapy for lung cancer and provides an overview of agents in development, clinical evidence to date, and implications for clinical application.
MeSH terms
-
Animals
-
Drug Delivery Systems / methods*
-
Humans
-
Immunity, Cellular / drug effects*
-
Immunologic Factors / administration & dosage
-
Immunotherapy / methods
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / immunology*
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
-
Programmed Cell Death 1 Receptor / immunology
-
Programmed Cell Death 1 Receptor / metabolism*
-
Signal Transduction / drug effects
-
Signal Transduction / immunology
-
Treatment Outcome
Substances
-
Immunologic Factors
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor